Enanta Pharmaceuticals Inc (ENTA): Operating Cash Flow
-$19.27M
Year ended 2025-09-30
-$35.32M
Trailing 12 months to 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-09-30 | -$19.27M | n/m | 2025-11-19, From 2024-10-01 |
| 2024-09-30 | -$78.76M | n/m | 2025-11-19, From 2023-10-01 |
| 2023-09-30 | -$103.15M | n/m | 2025-11-19, From 2022-10-01 |
| 2022-09-30 | -$84.78M | n/m | 2024-11-27, From 2021-10-01 |
| 2021-09-30 | -$70.00M | n/m | 2023-11-22, From 2020-10-01 |
| 2020-09-30 | $7.09M | -90.1% | 2022-11-23, From 2019-10-01 |
| 2019-09-30 | $71.42M | +144.4% | 2021-11-24, From 2018-10-01 |
| 2018-09-30 | $29.22M | -44.5% | 2020-11-25, From 2017-10-01 |
| 2017-09-30 | $52.65M | +47.0% | 2019-11-27, From 2016-10-01 |
| 2016-09-30 | $35.81M | -53.3% | 2018-11-29, From 2015-10-01 |
| 2015-09-30 | $76.67M | +280.0% | 2017-12-11, From 2014-10-01 |
| 2014-09-30 | $20.18M | +89.4% | 2016-12-09, From 2013-10-01 |
| 2013-09-30 | $10.65M | -52.9% | 2013-12-18, From 2012-10-01 |
| 2012-09-30 | $22.62M | -5.8% | 2013-12-18, From 2011-10-01 |
| 2011-09-30 | $24.02M | n/a | 2013-12-18, From 2010-10-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Enanta Pharmaceuticals Inc (ENTA) | 2025-09-30 | -$19.27M | n/m |
| Spero Therapeutics, Inc. (SPRO) | 2025-12-31 | -$12.62M | n/m |
| Fortress Biotech, Inc. (FBIO) | 2025-12-31 | -$65.78M | n/m |
| Kura Oncology, Inc. (KURA) | 2025-12-31 | -$64.06M | n/m |
| Nuvation Bio Inc. (NUVB) | 2025-12-31 | -$173.43M | n/m |
| Tango Therapeutics, Inc. (TNGX) | 2025-12-31 | -$138.89M | n/m |
| Rockwell Medical, Inc. (RMTI) | 2025-12-31 | -$659.0K | n/m |
| Journey Medical Corp (DERM) | 2025-12-31 | -$12.44M | n/m |
| Viridian Therapeutics, Inc. (VRDN) | 2025-12-31 | -$276.39M | n/m |
Compare ENTA, SPRO, FBIO, KURA side by side · Screen every company in Pharmaceutical Preparations ↗